Diabetes Medications Linked to Lower Kidney Stone Risk: Study
Written by Arushi Sharma
Good news for people with type 2 diabetes and a high risk of kidney stones! A study published in JAMA Internal Medicine suggests that SGLT2 inhibitors, a class of diabetes medications, may significantly reduce your risk of developing these painful stones.
A study conducted by researchers at Mass General Brigham has revealed that the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors, a class of diabetes medications, is associated with a decreased risk of developing kidney stones.
The study, published in JAMA Internal Medicine, analyzed data from three nationwide databases involving 716,406 adults with type 2 diabetes, ANI reported.
The research compared individuals taking SGLT2 inhibitors with those taking two other classes of diabetes medications—GLP1 receptor agonists and dipeptidyl peptidase 4 (DPP4) inhibitors.
The results indicated that patients initiating SGLT2 inhibitors had a 30% lower risk of kidney stone development compared to those taking GLP1 agonists and a 25% lower risk compared to those taking DPP4 inhibitors.
The findings remained consistent across various demographics, including sex, race/ethnicity, history of chronic kidney disease, and obesity.
Dr. Julie Paik, corresponding author and member of the Division of Pharmacoepidemiology and Pharmacoeconomics, as well as the Division of Renal (Kidney) Medicine at Brigham and Women's Hospital, noted that these findings could be valuable in guiding clinical decisions for diabetes patients at risk of kidney stones.